Candida (CD-1)
With a ratio of 20:1, the high CBD levels and their associated anti-psychotic capabilities outweigh the relatively small amounts of THC removing the “high” and providing the patient with a non-psychoactive cannabis Sativa L plant.
Breeder: MM Genetics
Variety: Mostly Sativa
THC Content: 0.5%
CBD Content: 11-20%
CBD to THC ratio: 20:1
Sex: Feminised
Flowering Time: 9 Weeks
Yield: High
Medicinal Use: Depression, ADHD, Anorexia, Epilepsy, Autism.
CD-1 is a high yielding feminized strain with a unique lemon flavor and aroma that compliment its medicinal properties.
Candida will noticeably produce two different phenotypes; a sativa and an indica. Initial research has suggested that the sativa phenotype will produce lower, whispier yields often associated with sativa strains. We have noticed to date that the sativa pheno produces higher CBD counts. In comparison, the indica pheno will produce bigger, denser yields with lower CBD levels but still with significant CBD content. The sativa can be harder to manage and will have larger distances between the internodes making the plants more vulnerable.
In 2014, the founders of MM Genetics witnessed the therapeutic nature of cannabis while treating a founder’s mother. Candida Green was battling late-stage pancreatic cancer. Hours after her first dose of cannabis oil her pain was significantly reduced and in the following weeks, her quality of life dramatically improved.
The website medicalmarijuana.co.uk was set up shortly after her death with the simple aim of raising awareness of the real medicinal properties of the Cannabis Sativa L plant.
The benefits of the cannabis oil were clearly visible to those around her and awoke a passion and deep interest in the use of cannabis as a medicine. A concept to source and sell seeds with exciting therapeutic benefits was developed while raising awareness in local communities.
Through the organisation’s interaction with patients and cannabis communities worldwide, it quickly became apparent that the need was for cannabis genetics that targeted specific symptoms.
Medical Marijuana Genetics was formed in 2015 and began working with award-winning breeders and caregivers. A line of CBD dominant cannabis strains has since been created and has gone on to win several awards including best CBD strain at Spannabis 2017. These CBD cannabis seeds are now available here.
The laboratory tests of our flagship strain, Candida, revealed a CBD count of 20% with a THC count of under 1%. This percentage is the highest known count in a CBD-rich phenotype ever created in Europe.
Following the overwhelming success of their first grow, Medical Marijuana Genetics created a further 12 elite strains from Candida crosses, all of which have been genetically selected to provide access (within the lawful jurisdiction) to the broadest range of therapeutics that the cannabis plant, and CBD in particular, has to offer. This includes treatments for symptoms such chronic pain, inflammation, seizures, convulsions, gastrointestinal disorders, nausea, vomiting, skin conditions, bacterial infections, anxiety, depression, cancer cell growth and much more.